Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michele P. Lambert
Fostamatinib and Thrombopoietin Receptor Agonists to Optimize Personalized Chronic Immune Thrombocytopenia Management
Submitted: 27 January 2026 You are already at the latest version Key mechanisms underlying immune thrombocytopenia (ITP) pathophysiology include impaired platelet production and macrophage-mediated platelet destruction, the latter of which is the disease driver in more than half of patients. Traditional sequential treatment approaches achieve suboptimal responses in many patients.
Ras‐associated autoimmune lymphoproliferative disorder
CONFLICT OF INTEREST STATEMENT KES: None. ML: ML is an advisory board member for Octapharma, Dova, Principia, Rigel, Argenx, PDSA, 22qSociety and CdLS Foundation; a consultant for Novartis Dova, Principia, Argenx, Rigel, Sobi, Sanofi and Janssen; and has received research funding from FWGBD, PDSA, NIH, Sysmex, Novartis, Principia, Argenx, Dova, Octapharma and Sanofi.
Ras‐associated autoimmune lymphoproliferative disorder
CONFLICT OF INTEREST STATEMENT KES: None. ML: ML is an advisory board member for Octapharma, Dova, Principia, Rigel, Argenx, PDSA, 22qSociety and CdLS Foundation; a consultant for Novartis Dova, Principia, Argenx, Rigel, Sobi, Sanofi and Janssen; and has received research funding from FWGBD, PDSA, NIH, Sysmex, Novartis, Principia, Argenx, Dova, Octapharma and Sanofi.
Sports participation in chronic immune thrombocytopenia: Safer than you thought?
DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.
A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group
CONFLICT OF INTEREST STATEMENT MPL is an advisory board member for Octapharma, Dova, Principia, Rigel and Shionogi, a consultant for Novartis, Shionogi, Dova, Principia, argenx, Rigel, Sobi, Sanofi and Janssen and has received research funding from Sysmex, Novartis, Rigel, Principia, Argenx, Dova, Octapharma and Astra Zeneca. REFERENCES 1, , , , , , et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23): 3829–3866.
A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group
CONFLICT OF INTEREST STATEMENT MPL is an advisory board member for Octapharma, Dova, Principia, Rigel and Shionogi, a consultant for Novartis, Shionogi, Dova, Principia, argenx, Rigel, Sobi, Sanofi and Janssen and has received research funding from Sysmex, Novartis, Rigel, Principia, Argenx, Dova, Octapharma and Astra Zeneca. REFERENCES 1, , , , , , et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23): 3829–3866.
Distinct immune trajectories in patients with chromosome 22q11.2 deletion syndrome and immune-mediated diseases
This paper is only available as a PDF. To read, Please Download here. Abstract Background Identification of biomarkers associated with immune-mediated diseases in 22q11.2 deletion syndrome is an evolving field. Objectives We used a carefully phenotyped cohort to study immune parameters associated with autoimmunity and atopy in 22q11.2 deletion syndrome. Our goal was to define biomarkers associated with immune-mediated disease in this syndrome.
Clinical updates in adult immune thrombocytopenia
Immune thrombocytopenia (ITP) is an acquired thrombocytopenia, defined as a platelet count 65 years).6⇓-8 A recent meta-analysis looked at risk of thrombosis in adult patients with ITP and concluded that patients with ITP have a higher risk of thromboembolism (TE) after ITP diagnosis of 1.6 (1.34, 1.86) based primarily on 2 large cohort studies.9 Interestingly, this same analysis showed a risk of TE prior to the ITP diagnosis in these patients with a prevalence of ∼8%.9 Secondary ITP (ITP...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michele P.
Contact Michele P., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack